RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.

The decline comes as US legislators have proposed incorporating biotechnology into the COINS Act's regulatory scope, which would restrict American capital flows into Chinese innovative pharmaceutical companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas business development transactions for domestic drug developers.

These dual-sided regulatory barriers directly undermine the core valuation logic for the sector's internationalization thesis. The broader biotechnology sector is experiencing significant selling pressure, with several peers also declining sharply during the session.